I thank the members who have supported my members’ business motion so enthusiastically over the past week or so.
Cystic fibrosis is a devastating genetic disease that has a terrible effect on patients and their families. From very early in life, children who have cystic fibrosis can exhibit multiple manifestations of the disease, including structural lung damage and abnormal lung clearance, which is a way of measuring airways’ health, and they also face nutritional impairments. The damage that they sustain to their lungs is progressive—it worsens over time and leads to increasing impairment of lung function. One consequence of that is that people with cystic fibrosis are more susceptible to life-threatening lung infections.
Due to the geographic origins of cystic fibrosis, the United Kingdom has a very high prevalence of the disease, accounting for some 12 per cent of the global population of patients. NHS Scotland has estimated that one in 24 Scots has a genetic mutation that can, if it is present in both parents, lead to a child being born with cystic fibrosis. According to the United Kingdom cystic fibrosis registry, there are approximately 900 people in Scotland with cystic fibrosis. They have a median age of just 21 and the median age of death is just 31. Only 5 per cent of cystic fibrosis sufferers will live to see their 50th birthday. I want members to think about that for a second. My 31st birthday is but a distant memory, but those with cystic fibrosis who reach that milestone have just a 5 per cent chance of getting to a 50th birthday.
I want members to think about what they would not have been able to do if they had died before one of those birthdays. I want them to think about the experiences that they would have missed and the memories that they have created with loved ones that would never have happened. That is the reality for so many people who suffer from cystic fibrosis. Surely it is incumbent on us to ensure that people with cystic fibrosis have the best chance of having as many of those experiences for as long as possible in order to create those memories. That is what Orkambi can do.
As I note in my motion, clinical data has shown that Orkambi is able to slow decline in lung function, which is the main cause of death from the condition, by 42 per cent. It has cut the number of infections that require hospitalisation by 61 per cent. According to the Cystic Fibrosis Trust, about 40 per cent of people with cystic fibrosis in Scotland would benefit from treatment with Orkambi.
The drug is different from traditional treatments for cystic fibrosis in that it is a precision medicine. Traditional treatments for cystic fibrosis aim to reduce symptoms and complications, but progressive damage still occurs, which means that symptoms and complications increase with age. However, precision medicine targets the root cause of cystic fibrosis—the dysfunctional protein that causes cystic fibrosis. Precision medicines have the potential to preserve or to restore lung function, and to slow decline and improve the life expectancy and quality of life of patients.
Other precision medicines are being developed. Within five years, about 90 per cent of people with cystic fibrosis could be treated with new medicines that could transform cystic fibrosis from being a condition that kills people to one that they can live with. However, people with cystic fibrosis are worried that they will not get access to those life-changing medicines in Scotland because of the process that the medicines need to go through to become available on the national health service here. Orkambi received its licence two years ago, but is still not available here, although it is available to all eligible patients in Austria, Denmark, Germany, Luxembourg, the Netherlands, Italy, Ireland, Greece and the United States. It is still unavailable here because the Scottish Medicines Consortium announced in 2016 that it was unable to recommend the drug due to its cost, despite acknowledging that the drug is “important and effective”.
Since then, people who suffer from cystic fibrosis and organisations including the Cystic Fibrosis Trust have called for negotiations and a fair sustainable pricing deal for Orkambi. Sadly, there has been no progress, so people with cystic fibrosis are still waiting for help while their health and quality of life decline.
I know that elsewhere there has been success in negotiating prices with Governments. Vertex Pharmaceuticals, the company that makes Orkambi, also makes Kalydeco, which is another cystic fibrosis precision medication. Kalydeco is available in Scotland via the new medicines fund, following the intervention of ministers in 2013, but Orkambi has not had the same intervention. That means that inequality has been created among cystic fibrosis patients, depending on the treatment that they require.
A good example of a different way of opening up access to new medicines is the Republic of Ireland’s approach. By agreeing a portfolio approach, which is a long-term solution, new medicines for cystic fibrosis have become available for patients in that country when they are manufactured and licensed. Deals of that type mean that the overall prices of current and future medicines are capped for a set amount of time, which means that a doctor can move a patient on to new medicines if they would better address that patient’s particular type of cystic fibrosis. That approach has major benefits, and science is now moving so quickly that I worry that the old models for bringing medicines into the system no longer work.
I want to quote Mr and Mrs O’Neill of Lenzie, from my region, who wrote to me and encapsulated what I think the debate is all about. They say:
“My son is 18 months old and he is the future—he should not be denied access to precision medicines that will support him to live the life he so rightly deserves. Although not now, Conan’s health will deteriorate at some point—his life should not be shortened even further by denying Conan and the other 907 people in Scotland who live with cystic fibrosis access to the medicines that they need. It’s not just about Orkambi, it’s about what comes after Orkambi and that is why it is so important that an approach can be agreed that allows access to the pipeline of future life-giving medications and treatments. Scotland led the way with access to Kalydeco and must lead the way again.”
We must have unity throughout the United Kingdom. The National Institute for Health and Care Excellence has approved the use of Orkambi in England and Wales. We should do the same in Scotland.